Please assess the completion status of the following clinical trial:

Trial Title: Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Men/women aged 18-80 years.~2. Low HDL-C, adjusted for baseline statin use~   1. Not on statin: Men with HDL \<= 40 or women with HDL \<= 50 mg/dL~  2. On statin: Men with HDL \<= 42 or women with HDL \<= 52 mg/dL~3. TG/HDL ratio \>= 3.5~4. Able to understand and agree to informed consent~5. Women of child-bearing age must test negative on a urine pregnancy test and agree to use reliable birth control during the study and for 1 month after last dose of study drugs. Reliable methods include oral contraceptives, a barrier method, intrauterine device, partner with vasectomy, or abstinence.~6. Willing to be available for study duration and follow study procedures~Exclusion Criteria:~1. Subjects with following lipoprotein disorders:~   1. Patients on high-potency lipid-lowering regimen, defined as two or more prescription lipid-altering medications (excluding fish oils) where one is a high-dose statin (40 mg/day of rosuvastatin, 80 mg/day of other approved statins). Those on combination therapy with a lower statin dose or those taking high-dose statin monotherapy (excluding fish oils) may participate. Patients will switch to atorvastatin 10 mg and/or wash off other lipid medications to participate~  2. LDL \> 190 mg/dL~  3. TG \> 750 mg/dL or pancreatitis from triglyceridemia, regardless of current TG levels~  4. Dysbetalipoproteinemia (VLDL/TG \> 0.3 -AND- TG \> 200 mg/dL).~2. Use of non-statin lipid therapy prior to study initiation is exclusionary if (n.b. washout of non-statins is permitted):~   1. Niacin \> 250 mg/ day within 6 weeks: Advicor, Niaspan, Niacor, Simcor, Slo-Niacin, or supplemental niacin~  2. Fibrates within 12 weeks: fenofibrate (Antara, Lofibra, Tricor, Triglide), gemfibrozil (Lopid), or clofibrate~  3. Enterically active drugs within 4 weeks: colestipol, cholestyramine, colesevelam, ezetimibe, orlistat.~  4. Red yeast rice during the treatment phase of the study (i.e. must be switched to study statin)~  5. Fish oil \> 2 g/day within 4 weeks: Lovaza (née Omacor), numerous supplements~  6. Altered dose of a selective estrogen receptor modulator (SERM) within 4 weeks~3. Intolerance to statin, fibrate, aspirin, deuterated leucine, or niacin~4. Contraindications to medications, including chronic muscle disease, history of rhabdomyolysis, moderate-severe gout, severe peptic ulcer disease, bleeding disorders, and aspirin-sensitive asthma.~5. Diabetics, or fasting glucose \> 110 mg/dL on two different days during screening, or use of anti-diabetic medications within 6 weeks of screening visit~6. Chronic renal insufficiency, nephrotic syndrome, or current serum creatinine \> 2.5 mg/dL, or GFR \< 60 mL/min/1.73m2 by the MDRD equation.~7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin \> 2 X the upper limit of normal (ULN), albumin of \< 2.5 mg/dL, prothrombin time (PT) \> 1.5 X ULN, partial thromboplastin time (PTT) \> 1.5 X ULN, or current active hepatobiliary disease~8. Hemoglobin (Hgb) \< 10 mg/dL~9. Weight \< 110 lbs~10. Use of an investigational drug within 6 weeks prior to screening visit~11. Major surgery within the previous 6 weeks, or anticipated major surgery during course of study, or any history of organ transplant~12. Non-skin malignancy within previous 5 years~13. Drug abuse within past 3 years, or regular alcohol use \>14 drinks/week~14. Women who are pregnant, plan to conceive, or breast-feed~15. Any serious or unstable medical or psychological conditions that, in investigator's opinion would compromise subject safety or successful participation.~16. Currently adhering to, planning to adhere to or used within 3 months prior to screening, supplements intended for weight loss or adopt diets with aggressive carbohydrate restrictions, such as but not limited to Atkins or South Beach diets.~17. Currently taking Vitamin A supplements (multivitamins allowed)(washout permitted)~18. Excluded concomitant medications~    1. Immunosuppressants within 2 months prior to screening or are likely to require such treatment during the course of the study~   2. Warfarin.~19. Disinclination to dairy products (e.g. inviolable dietary restrictions or lactose intolerance to an 8oz glass of milk despite lactase supplementation) Lactase supplementation is allowed during the study.~20. Regular consumers of grapefruit juice, or currently taking medications metabolized by CYP 3A4 (cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone)~21. History of pancreatitis or gallbladder disease~22. History of coronary heart disease~23. History of intolerance/adverse reaction to heparin or women who have dysfunctional uterine bleeding~24. Thrombocytopenia at screening~25. History of intracerebral or significant GI bleed~26. Subjects doing regular strenuous activity or have a CK \> 3x ULN at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: ACTIVE_COMPARATOR): atorvastatin 10 mg/day by mouth for a total duration of 4 weeks
- ABT335 (Type: ACTIVE_COMPARATOR): ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8
- ER niacin (Type: ACTIVE_COMPARATOR): ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).